Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) was down 1.2% during trading on Thursday . The company traded as low as $11.73 and last traded at $11.87, with a volume of 190,551 shares changing hands. The stock had previously closed at $12.01.

A number of equities research analysts have commented on MNTA shares. JPMorgan Chase & Co. reissued a “buy” rating on shares of Momenta Pharmaceuticals in a research note on Wednesday, May 4th. Brean Capital reissued a “buy” rating and issued a $19.00 price objective on shares of Momenta Pharmaceuticals in a research note on Wednesday, May 4th. Zacks Investment Research raised Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, April 27th. Cowen and Company reissued a “hold” rating on shares of Momenta Pharmaceuticals in a research note on Sunday. Finally, Goldman Sachs Group Inc. started coverage on Momenta Pharmaceuticals in a research note on Monday, June 6th. They issued a “neutral” rating and a $14.00 price objective for the company. Five research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Momenta Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $17.80.

The company has a 50 day moving average price of $11.32 and a 200 day moving average price of $10.44. The firm’s market cap is $811.50 million.

Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its earnings results on Thursday, August 4th. The biotechnology company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.01. The firm had revenue of $26.40 million for the quarter, compared to analysts’ expectations of $23.55 million. During the same quarter last year, the company posted ($0.04) EPS. The firm’s revenue was down 41.2% on a year-over-year basis. Equities research analysts anticipate that Momenta Pharmaceuticals Inc. will post ($1.25) EPS for the current fiscal year.

In other Momenta Pharmaceuticals news, President Craig A. Wheeler sold 5,880 shares of the company’s stock in a transaction that occurred on Friday, May 20th. The stock was sold at an average price of $10.18, for a total transaction of $59,858.40. Following the transaction, the president now owns 349,521 shares in the company, valued at approximately $3,558,123.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Other hedge funds and institutional investors have recently bought and sold shares of the company. Morgan Stanley increased its position in Momenta Pharmaceuticals by 123.0% in the fourth quarter. Morgan Stanley now owns 69,759 shares of the biotechnology company’s stock worth $1,035,000 after buying an additional 38,470 shares during the period. Rhumbline Advisers increased its position in Momenta Pharmaceuticals by 9.9% in the fourth quarter. Rhumbline Advisers now owns 75,638 shares of the biotechnology company’s stock worth $1,122,000 after buying an additional 6,835 shares during the period. GSA Capital Partners LLP increased its position in Momenta Pharmaceuticals by 298.9% in the fourth quarter. GSA Capital Partners LLP now owns 88,251 shares of the biotechnology company’s stock worth $1,310,000 after buying an additional 66,130 shares during the period. Swiss National Bank increased its position in Momenta Pharmaceuticals by 2.6% in the fourth quarter. Swiss National Bank now owns 91,500 shares of the biotechnology company’s stock worth $1,358,000 after buying an additional 2,300 shares during the period. Finally, California State Teachers Retirement System increased its position in Momenta Pharmaceuticals by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 113,170 shares of the biotechnology company’s stock worth $1,679,000 after buying an additional 1,801 shares during the period.

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.